Friday, November 13, 2026
Description
Preclinical Alzheimer's Disease (PCAD) is a silent, long-term phase of Alzheimer’s biology, detectable only through advanced tests. While it carries risk, not everyone progresses to dementia, and early detection is key for future preventive strategies. The symposium will highlight the earliest stage of the disease, when biological changes such as amyloid plaque buildup and tau tangle formation are already occurring in the brain, but no cognitive symptoms like memory loss or confusion have appeared. This phase can last years to decades before symptoms develop, and in some cases, people may never progress to dementia. The early changes to the brain in preclinical AD can be very subtle. As medical professionals do not screen for preclinical AD, they usually only notice these changes in experimental research or when a person has diagnostic tests for another reason. This symposium on Preclinical Alzheimer’s Disease (PCAD) will address physicians’ limited knowledge of the biological changes, emerging biomarkers, risk factors, and evolving diagnostic criteria associated with Alzheimer’s disease before noticeable cognitive symptoms appear.
Registration information to follow shortly....
Dates and Times
Start: 11/13/2026 8:00 AM
End: 11/13/2026 11:00 AM
Objectives
- Learn about the importance of healthy aging with a focus on vision, hearing, dental health, immunizations, diet, exercise and sleep which can help decrease risk for Alzheimer’s disease.
- Discuss Multisensory Integration (MSI) and demonstrate its importance in aging research, cognitive impairment/preclinical AD and learn about a technology-based early biomarker for cognitive impairment (Catch U).
- Review preclinical Alzheimer's disease (PCAD) and the biological changes that occur years before the onset of clinical symptoms, including advances in detection through blood-based and neuroimaging biomarkers and learn about cutting-edge clinical trials targeting amyloid and tau pathology.
Speakers
Accreditation
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 3.00 AMA PRA Category 1 Credits ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.